ID Source | ID |
---|---|
PubMed CID | 665449 |
CHEMBL ID | 259018 |
CHEBI ID | 92433 |
Synonym |
---|
STL348854 |
tert-butyl (2-{5-[(2,4-dichlorobenzyl)sulfonyl]-1,3,4-oxadiazol-2-yl}ethyl)carbamate |
smr000046713 |
MLS000041932 , |
CHEMBL259018 |
tert-butyl n-[2-[5-[(2,4-dichlorophenyl)methylsulfonyl]-1,3,4-oxadiazol-2-yl]ethyl]carbamate |
MLS002583822 |
HMS2273E06 |
AKOS022098623 |
n-[2-[5-[(2,4-dichlorophenyl)methylsulfonyl]-1,3,4-oxadiazol-2-yl]ethyl]carbamic acid tert-butyl ester |
n-[2-[5-(2,4-dichlorobenzyl)sulfonyl-1,3,4-oxadiazol-2-yl]ethyl]carbamic acid tert-butyl ester |
bdbm66247 |
cid_665449 |
CHEBI:92433 |
850749-39-2 |
Q27164169 |
ml025 |
Class | Description |
---|---|
dichlorobenzene | Any member of the class of chlorobenzenes carrying two chloro groups at unspecified positions. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 0.2328 | 0.0447 | 17.8581 | 100.0000 | AID1002; AID485294; AID485341 |
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 0.7943 | 0.0251 | 20.2376 | 39.8107 | AID886 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 0.7943 | 0.0251 | 20.2376 | 39.8107 | AID886 |
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 25.1189 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 0.3981 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
TDP1 protein | Homo sapiens (human) | Potency | 2.1145 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 1.5849 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 0.8913 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
Smad3 | Homo sapiens (human) | Potency | 10.0000 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 2.8184 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 1.4125 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
67.9K protein | Vaccinia virus | Potency | 17.4882 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
P53 | Homo sapiens (human) | Potency | 25.1189 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
alpha-galactosidase | Homo sapiens (human) | Potency | 0.3162 | 4.4668 | 18.3916 | 35.4813 | AID2107 |
IDH1 | Homo sapiens (human) | Potency | 18.3564 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 8.9125 | 0.0165 | 25.3078 | 41.3999 | AID602332 |
cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 12.4435 | 31.6228 | AID902 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 2.5119 | 0.0018 | 15.6638 | 39.8107 | AID894 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 0.7943 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 19.9526 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 8.4368 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 14.7333 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
geminin | Homo sapiens (human) | Potency | 18.2003 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 31.6228 | 0.0200 | 10.7869 | 31.6228 | AID912 |
neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 10.0000 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 31.6228 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
Alpha-synuclein | Homo sapiens (human) | Potency | 10.0000 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
XBP1 | Homo sapiens (human) | IC50 (µMol) | 4.4400 | 0.1600 | 5.4049 | 10.0000 | AID504313 |
fatty acid synthase | Homo sapiens (human) | IC50 (µMol) | 5.3250 | 0.1660 | 5.6472 | 18.2000 | AID624326; AID624327 |
DNA damage-inducible transcript 3 protein | Mus musculus (house mouse) | IC50 (µMol) | 10.0000 | 0.1600 | 3.9959 | 10.0000 | AID504322 |
Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 (µMol) | 4.2200 | 0.0002 | 2.4585 | 9.9600 | AID1640021 |
Cruzipain | Trypanosoma cruzi | IC50 (µMol) | 282.5000 | 0.0002 | 2.0450 | 8.0000 | AID318871; AID318872 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, BCL-2-RELATED PROTEIN A1 | Homo sapiens (human) | EC50 (µMol) | 350.0000 | 8.0570 | 121.1218 | 338.0000 | AID2765 |
recombinase A | Mycobacterium tuberculosis H37Rv | EC50 (µMol) | 192.3300 | 0.0180 | 23.2882 | 287.6000 | AID434968; AID435010 |
bcl-2-like protein 11 isoform 1 | Homo sapiens (human) | EC50 (µMol) | 350.0000 | 8.0570 | 121.1218 | 338.0000 | AID2765 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
replicative DNA helicase | Mycobacterium tuberculosis H37Rv | AC50 | 190.8055 | 0.0570 | 30.7482 | 325.3000 | AID449749; AID449750 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID318871 | Inhibition of cruzain | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. |
AID318866 | Inhibition of beta-lactamase AmpC in presence of 0.1% Triton X-100 | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. |
AID318867 | Inhibition of chymotrypsin | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. |
AID318870 | Inhibition of malate dehydrogenase in presence of 0.1% Triton X-100 | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. |
AID318872 | Inhibition of cruzain in presence of 0.01% Triton X-100 | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. |
AID318865 | Inhibition of beta-lactamase AmpC | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. |
AID318868 | Inhibition of chymotrypsin in presence of 0.1% Triton X-100 | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. |
AID318869 | Inhibition of malate dehydrogenase | 2008 | Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8 | Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.41) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |